{'fraction_non_alphanumeric': 0.03260869565217391, 'fraction_numerical': 0.01884057971014493, 'mean_word_length': 5.30593607305936, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Immunohistochemical Studies on Matrix Metalloproteinase‐9 (MMP‐9) and Type‐IV Collagen in Endometrial Carcinoma

Immunohistochemical staining of MMP‐9 and the type‐IV collagen was performed on paraffin sections of endometrial carcinoma. Immunostaining in 129 cases of endometrial cancer detected MMP‐9 in 19.0% of the cases. MMP‐9 positive was shown in 30% of the cases with vessel invasion, and in 12.7% of the cases without vessell invasion (p < 0.05). MMP‐9 showed positive in many cases with poor differentiation and lymph node metastasis, but still failed to achieve statistical significance. MMP‐9 staining did not correlate with disease outcomes. We can not clarify that MMP‐9 is associated with tumor‐cell invasion and metastasis. Type‐IV collagen deposition at the tumor‐stromal border was studied in 58 cases of endometrial carcinoma in which disruptions were seen in varying degrees. The type‐IV collagen in the primary lesion decreased as the differentiation decreased. Even in the lymph node metastasis lesions, the type‐IV collagen was stained and was almost in agreement with the primary lesions. In the primary lesions, there was no relationship between MMP‐9 staining and the type‐IV collagen. It was suggested that the type‐IV collagen observed in endometrial carcinoma was more concerned with the differentiation of the tumor than with the degradation by MMP‐9.